International Journal of Medical and Pharmaceutical Research
2024, Volume-5, Issue-3
Original Research Article
Clinical, functional, Radiological outcome of Intramedullary nailing versus minimally invasive percutaneous plate osteosyntheses for distal third tibia fracture
Published
June 15, 2024
Abstract

Background: Distal third tibial fractures are challenging to treat due to the limited soft tissue coverage and the proximity to the ankle joint. This study aimed to compare the clinical, functional, and radiological outcomes of intramedullary nailing (IMN) and minimally invasive percutaneous plate osteosynthesis (MIPPO) for distal third tibial fractures. Methods: A prospective, randomized controlled trial was conducted, including 36 patients with distal third tibial fractures (AO/OTA 43-A1, A2, A3). Patients were randomly allocated to either the IMN group (n=18) or the MIPPO group (n=18) and followed up for 12 months. The primary outcome was time to union, and secondary outcomes included functional scores (AOFAS and OMAS), complications, and radiographic parameters. Results: The mean time to union was significantly shorter in the IMN group compared to the MIPPO group (16.2 ± 3.4 weeks vs 18.6 ± 4.1 weeks, p=0.042). There were no significant differences in functional scores, complications, or radiographic outcomes between the groups. Subgroup analysis based on fracture classification showed no significant differences between the groups. Multivariate analysis identified smoking status, fracture severity, and treatment group as significant factors influencing time to union. Conclusion: IMN was associated with a shorter time to union compared to MIPPO in the treatment of distal third tibial fractures, with similar functional outcomes and complication rates. These findings suggest that IMN may be the preferred treatment option, especially in non-smokers and less severe fracture types. Future research should focus on larger, multicenter trials with longer follow-up periods to confirm these findings and assess long-term outcomes.

Recommended Articles
Loading Image...
Volume-5, Issue-3
Citations
1585 Views
304 Downloads
Share this article
License
Copyright (c) International Journal of Medical and Pharmaceutical Research
pdf Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.
IJMPR open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.
Logo
International Journal of Medical and Pharmaceutical Research
About Us
The International Journal of Medical and Pharmaceutical Research (IJMPR) is an EMBASE (Elsevier)–indexed, open-access journal for high-quality medical, pharmaceutical, and clinical research.
Follow Us
© Copyright IJMPR | All Rights Reserved